FRANCISCO DE PAULA
TELLEZ PEREZ
Profesor asociado de Ciencias de la Salud
Complejo Hospitalario Torrecárdenas de Almería
Almería, EspañaPublikationen in Zusammenarbeit mit Forschern von Complejo Hospitalario Torrecárdenas de Almería (26)
2024
2023
-
Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice
Journal of Antimicrobial Chemotherapy, Vol. 78, Núm. 10, pp. 2591-2596
2022
-
High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use
Journal of Infection, Vol. 85, Núm. 3, pp. 322-326
2021
-
Progression to hepatitis C virus micro-elimination in people living with HIV in Spain
Clinical Microbiology and Infection
2019
-
DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients
Medicine (United States), Vol. 98, Núm. 32
-
Early emergence of opportunistic infections after starting direct-acting antiviral drugs in HIV/HCV-coinfected patients
Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 48-54
-
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world
Journal of Hepatology, Vol. 71, Núm. 5, pp. 876-888
-
Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks
Journal of Infection, Vol. 79, Núm. 1, pp. 30-35
-
Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients
HIV Medicine, Vol. 20, Núm. 6, pp. 359-367
-
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort
PLoS ONE, Vol. 14, Núm. 8
-
Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy
Journal of Hepatology, Vol. 71, Núm. 1, pp. 45-51
-
The simplification of the diagnosis process of chronic hepatitis C is cost-effective strategy
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 10, pp. 634-641
2018
-
Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort
Journal of Viral Hepatitis, Vol. 25, Núm. 6, pp. 699-706
-
Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice
HIV Clinical Trials, Vol. 19, Núm. 1, pp. 23-30
2017
-
HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study
HIV Clinical Trials, Vol. 18, Núm. 3, pp. 126-134
-
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494
-
Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection
Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8
2016
-
Hepatic safety of rilpivirine/emtricitabine/tenofovir disoproxil fumarate fixed-dose single-tablet regimen in HIV-infected patients with active hepatitis C virus infection: The hepatic study
PLoS ONE, Vol. 11, Núm. 5
-
Liver toxicity of current antiretroviral regimens in HIV-infected patients with chronic viral hepatitis in a real-life setting: The HEPAVIR SEG-HEP Cohort
PLoS ONE, Vol. 11, Núm. 2
-
No evidence of firstly acquired acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain: A multicentric retrospective study from 2000-2014
BMC Infectious Diseases, Vol. 16, Núm. 1